Endocyte Announces Presentation at the European Society for Medical Oncology (ESMO)
September 05 2017 - 4:01PM
Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small
molecule drug conjugates (SMDCs) and companion imaging agents for
personalized therapy, today announced that a poster will be
presented at the European Society for Medical Oncology (ESMO),
being held in Madrid, Spain, Sept. 8-12, 2017.
Presentation is as follows:
Abstract #: 793PDTitle: “Phase 1 Study of the PSMA-targeted
small-molecule drug conjugate EC1169 in patients with metastatic
castrate-resistant prostate cancer (mCRPC)”When: Sunday, Sept. 10,
2017, from 9:15 – 10:30 AM CESTSession Type: Poster Discussion
SessionTitle: Genitourinary tumours, prostateLocation: Bilbao
Auditorium
About EC1169 and the Phase 1 Trial
EC1169 is an investigational therapeutic SMDC constructed of a
high affinity PSMA-targeting ligand conjugated through a
bioreleasable linker system to a potent microtubule inhibitor,
tubulysin B hydrazide (TubBH). Patient PSMA-status is determined
using the investigational companion imaging agent, EC0652. EC1169
and EC0652 are currently being evaluated in a Phase 1b study in up
to 50 taxane-exposed mCRPC patients at a maximum clinical EC1169
dose of 6.5 mg/m2. Endocyte has stopped enrollment of taxane-naïve
mCRPC patients (ClinicalTrials.gov Identifier: NCT02202447).
The open-label, multicenter, non-randomized study is divided
into two parts. The first part, phase 1a, of the study, now
complete, was designed to determine the maximum clinical dose and
recommended Phase 2 dose of EC1169 in patients with mCRPC.
Endocyte is currently enrolling the second part, phase 1b, of
the study, which is designed to evaluate the safety and efficacy of
EC1169 in taxane-exposed patients, with a primary study endpoint of
radiographic progression free survival in patients selected as
PSMA-positive. The trial is expected to complete enrollment in Q3
2017 with a more mature endpoint assessment by year-end.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing
targeted therapies for the treatment of cancer and other serious
diseases. Endocyte uses its proprietary drug conjugation technology
to create novel SMDCs and companion imaging agents for personalized
targeted therapies. The company’s SMDCs actively target receptors
that are over-expressed on diseased cells relative to healthy
cells. This targeted approach is designed to enable the treatment
of patients with highly active drugs at greater doses, delivered
more frequently and over longer periods of time than would be
possible with the untargeted drug alone. The companion imaging
agents are designed to identify patients whose disease
over-expresses the target of the therapy and who are therefore more
likely to benefit from treatment. In addition, the company
continues to pursue applications of the SMDC platform and is
working to bring assets toward clinical development in several
areas, including EC2629, its dual-targeted DNA crosslinker drug
that can attack both TAMs and cancer cells, and its CAR T-Cell SMDC
adaptor platform. For additional information, please visit
Endocyte’s website at www.endocyte.com
Contacts:
Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, stephanie@sternir.com
Endocyte, Inc. (delisted) (NASDAQ:ECYT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Endocyte, Inc. (delisted) (NASDAQ:ECYT)
Historical Stock Chart
From Sep 2023 to Sep 2024